Department of Urology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan.
Anticancer Res. 2010 Feb;30(2):593-9.
To examine expression profiles of LewisX(Le(x))-related antigens, which have a possible role in hematogenous metastatic spread in various malignancies, in renal cell cancer (RCC) tissue in order to evaluate their prognostic value for patients with low-stage RCC.
Fifty-two patients with pT1-2N0M0 disease were evaluated for their expression patterns of Le(x)-related antigens using FH6 and CSLEX1 antibodies for sLe(x) and AG223 for 6-sulfo Le(x), immunohistochemically.
None of the expression levels of Le(x)-related antigens directed by the three antibodies related to the clinical outcomes of patients with low-stage RCC. However, combined use of FH6 and CSLEX1 antibodies enabled prognostic prediction, namely that patients with low intensity with FH6 and high intensity with CSLEX1 had a higher chance of disease progression and poor survival.
Expression levels Le(x)-related antigens determined by combined use of FH6 and CSLEX1 antibodies could be of value as a prognostic indicator for patients with low-stage RCC.
检测路易斯 X 相关抗原（Le(x)）的表达谱，这些抗原在各种恶性肿瘤的血源性转移扩散中可能具有作用，从而评估其在低分期肾细胞癌（RCC）患者中的预后价值。
使用 FH6 和 CSLEX1 抗体检测 sLe(x)，AG223 检测 6-硫酸-Le(x)，对 52 例 pT1-2N0M0 期疾病患者的 Le(x)相关抗原表达模式进行评估。
三种抗体所指向的 Le(x)相关抗原的表达水平均与低分期 RCC 患者的临床结局无关。然而，FH6 和 CSLEX1 抗体的联合使用可进行预后预测，即 FH6 低强度和 CSLEX1 高强度的患者发生疾病进展和生存不良的可能性更高。
联合使用 FH6 和 CSLEX1 抗体确定的 Le(x)相关抗原表达水平可能是低分期 RCC 患者的一种有价值的预后指标。
